KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Net Income (2018 - 2025)

Historic Net Income for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to -$32.0 million.

  • Esperion Therapeutics' Net Income fell 289.96% to -$32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$107.8 million, marking a year-over-year decrease of 16011.92%. This contributed to the annual value of -$4.8 million for FY2024, which is 9773.98% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Net Income of -$32.0 million as of Q3 2025, which was down 289.96% from -$13.4 million recorded in Q2 2025.
  • Esperion Therapeutics' 5-year Net Income high stood at $58.2 million for Q1 2024, and its period low was -$90.9 million during Q1 2021.
  • Moreover, its 5-year median value for Net Income was -$51.6 million (2023), whereas its average is -$42.9 million.
  • Its Net Income has fluctuated over the past 5 years, first surged by 19246.41% in 2024, then tumbled by 17129.71% in 2025.
  • Esperion Therapeutics' Net Income (Quarter) stood at -$69.1 million in 2021, then increased by 17.69% to -$56.8 million in 2022, then dropped by 1.02% to -$57.4 million in 2023, then soared by 63.71% to -$20.8 million in 2024, then plummeted by 53.58% to -$32.0 million in 2025.
  • Its Net Income was -$32.0 million in Q3 2025, compared to -$13.4 million in Q2 2025 and -$41.5 million in Q1 2025.